Voyager Therapeutics (VYGR) Stock
Biotech company developing gene therapies for brain diseases. Here's the price, business snapshot, and what's worth knowing about Voyager Therapeutics in August 2026.
Voyager Therapeutics (VYGR) is a clinical-stage biotechnology company developing gene therapies for serious neurological diseases. With a market capitalisation of about $275.68M, the firm focuses on adeno-associated virus (AAV)-based delivery platforms designed to provide sustained expression of therapeutic genes to the brain and central nervous system. Investors should know this is a high-risk, high-reward profile typical of small-cap biotechs: value depends heavily on clinical trial outcomes, regulatory decisions and the durability of scientific results. The company’s progress is driven by its pipeline milestones and any collaborations or licensing deals that can bring additional resources. Given the small market cap and clinical-stage assets, shares can be volatile and may react strongly to news. This summary is educational only and not personalised investment advice—prospective investors should review the company’s filings, clinical data and consider suitability given their risk tolerance.
About This Stock
VOYAGER THERAPEUTICS INC
VYGR
Current Price
$3.42
Potential 12 Month Profit
305.64%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Ticker
VYGR
Market Cap
$210.12M
Potential 12 Month Profit
305.64%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Voyager Therapeutics stock, anticipating significant price growth ahead.
Financial Health
Voyager Therapeutics is producing solid revenue and cash flow, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Development Pipeline
Clinical-stage gene therapies drive value and interest, but outcomes are binary and timelines can be long — monitor trial milestones closely.
Platform Technology
AAV-based delivery aims for durable effects in the brain; technological promise exists alongside scientific and regulatory uncertainty.
Market Considerations
Small market cap suggests potential upside but also liquidity and volatility risks; partnerships or licence deals can materially change the outlook.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.